Cell Therapeutics Will Pursue Xyotax Approval For Women With NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite having missed the primary endpoints in both STELLAR 3 and 4 trials, Cell Therapeutics plans to seek approval for Xyotax as first-line therapy for women with poor performance status, advanced non-small cell lung cancer.